CompaniesNoventia Pharma

Noventia Pharma

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (16)
View all

Total Trials

16

As Lead Sponsor

8

As Collaborator

8

Total Enrollment

12,632

By Phase

NA: 5PHASE2: 7PHASE3: 1PHASE1: 1

By Status

COMPLETED: 11RECRUITING: 2UNKNOWN: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
NCT03459079
NCT04849728
NCT05651724
Hover over trial bars to see details

Recent Trials

NCT07182292Collaborator
Effect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults
NANot yet recruiting
158 participants
Started: Oct 1, 2025 · Completed: Oct 1, 2027
NCT05651724Collaborator
Global Research Initiative for Patients Screening on MASH
N/ARecruiting
10,000 participants
Started: Jun 30, 2023 · Completed: Mar 31, 2031
NCT05781178Collaborator
Analysis of the Aetiological Factors of Malnutrition
N/ACompleted
271 participants
Started: May 2, 2023 · Completed: Sep 11, 2024
NCT05232071Lead Sponsor
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
PHASE2Completed
42 participants
Started: Jun 29, 2022 · Completed: Jun 4, 2024
NCT04849728Lead Sponsor
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
PHASE3Recruiting
1,000 participants
Started: Aug 19, 2021 · Completed: Sep 30, 2026
View all 16 trials →